Limitations
A limitation of this analysis was that risk factors other than the allocation adjustment factors were not used to randomize participants to olanzapine and placebo groups. Additionally, since the J-FORCE trial did not include patients who were treated with an anthracycline plus cyclophosphamide regimen, it is unclear whether the findings would apply to this regimen.